Search filters

List of works by William Wong

An adherence based cost-consequence model comparing bimatoprost 0.01% to bimatoprost 0.03%

scientific article published on 18 July 2013

Assessment of costs associated with adverse events in patients with cancer.

scientific article published on 13 April 2018

Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.

scientific article published on 2 February 2011

Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer

scientific article published on 27 February 2018

Cost effectiveness of pharmacogenomics: a critical and systematic review.

scientific article published on January 2010

Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer.

scientific article published on 9 March 2018

Effect of Brain Metastasis on Patient-Reported Outcomes in Advanced NSCLC Treated in Real-World Community Oncology Settings.

scientific article

Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study.

scientific article published on 14 August 2017

Oncologists' Perceptions of Drug Affordability Using NCCN Evidence Blocks: Results from a National Survey.

scientific article published on 16 February 2018

Predictors, Resource Utilization, and Short-term Costs of Laser Trabeculoplasty Versus Medication Management in Open-Angle Glaucoma.

scientific article

Prioritization in comparative effectiveness research: the CANCERGEN Experience.

scientific article

Real-World Clinical and Economic Outcomes and the Role of Bevacizumab in Patients With Non-Small-Cell Lung Cancer With Liver Metastases

scientific article published on 11 September 2019

Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA.

scientific article published on 22 December 2017

The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.

scientific article

The impact of copay assistance on patient out-of-pocket costs and treatment rates with ALK inhibitors

scientific article published on 01 March 2019

The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007)

scientific article